MoneyWorks4Me

Hikal informs about investors meet

02 Sep 2026 Evaluate

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Hikal has informed that Analysts and Institutional Investors (‘Participants’) are scheduled to visit the Company's Pune R&T centre and interact with the Company's officials, as per the details enclosed. Discussions will be based on publicly available information. 

The above information is a part of company’s filings submitted to BSE.

Hikal Share Price

228.00 -13.20 (-5.47%)
04-Sep-2026 14:16 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1899.10
Dr. Reddys Labs. 1158.00
Cipla 1380.55
Lupin 2110.00
Zydus Lifesciences 1129.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: